SCHEMBL4348629

SCHEMBL4348629

Cc1ccc(C)c(Nc2ccc(CN(C)CC(O)c3ccccc3)cc2)c1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.52
KMT2A Q03164 5/20 0.51
MEN1 O00255 4/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
KDM4E B2RXH2 2/20 0.51
TAAR1 Q96RJ0 1/20 0.48
CNR2 P34972 1/20 0.47
OPRM1 P35372 1/20 0.44
OPRD1 P41143 1/20 0.44
BRD4 O60885 1/20 0.42
AOC3 Q16853 1/20 0.39
ALDH1A1 P00352 1/20 0.38
MAPT P10636 3/20 0.36
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
BCHE P06276 1/20 0.36
ACHE P22303 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4346455 0.89 KDM4E (0.52) HTTKMT2AMEN1SMN1; SMN2KDM4E
SCHEMBL4346610 0.88 KDM4E (0.55) HTTKMT2AMEN1SMN1; SMN2KDM4E
SCHEMBL4343366 0.84 KDM4E (0.48) HTTKMT2AMEN1SMN1; SMN2KDM4E
SCHEMBL4343132 0.83 MEN1 (0.63) KMT2AMEN1SMN1; SMN2KDM4ETAAR1
SCHEMBL4340557 0.83 MEN1 (0.63) KMT2AMEN1SMN1; SMN2KDM4ETAAR1
SCHEMBL4347718 0.83 MEN1 (0.63) KMT2AMEN1SMN1; SMN2KDM4ETAAR1
SCHEMBL4348017 0.80 MEN1 (0.57) KMT2AMEN1SMN1; SMN2KDM4ETAAR1
SCHEMBL4343262 0.80 MEN1 (0.57) KMT2AMEN1SMN1; SMN2KDM4ETAAR1
SCHEMBL5963825 0.80 CNR2 (0.61) HTTKMT2AMEN1SMN1; SMN2KDM4E
SCHEMBL5964627 0.77 MEN1 (0.50) HTTKMT2AMEN1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275611-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-11-05 US claimed
EP-2007707-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR Boehringer Ingelheim International GmbH (DE) 2008-12-31 EP claimed
WO-2007118041-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-18 WO claimed
US-20090275611-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-11-05 US disclosed
US-20090275611-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-11-05 US disclosed
US-20090275611-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-11-05 US disclosed
EP-2007707-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR Boehringer Ingelheim International GmbH (DE) 2008-12-31 EP disclosed
WO-2007118041-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-18 WO disclosed
WO-2007118041-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275611-A1 Compounds Which Modulate The CB2 Receptor CNR1, CNR2, OPRL1 HTT 4022/4885KMT2A 2988/4885MEN1 4775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.